These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1616740)

  • 1. [The duration of the effect of norfloxacin on the fecal flora in cirrhosis patients].
    Soriano G; Guarner C; Tomás A; Anguera A; Mirelis B; Fernández C; Herrero M; Alonso C; Vilardell F
    Rev Esp Enferm Dig; 1992 May; 81(5):322-6. PubMed ID: 1616740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.
    Sàbat M; Kolle L; Soriano G; Ortiz J; Pamplona J; Novella MT; Villanueva C; Sainz S; Torras J; Balanzó J; Guarner C
    Am J Gastroenterol; 1998 Dec; 93(12):2457-62. PubMed ID: 9860409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
    Ortiz J; Vila MC; Soriano G; Miñana J; Gana J; Mirelis B; Novella MT; Coll S; Sábat M; Andreu M; Prats G; Solá R; Guarner C
    Hepatology; 1999 Apr; 29(4):1064-9. PubMed ID: 10094947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis.
    Runyon BA; Borzio M; Young S; Squier SU; Guarner C; Runyon MA
    Hepatology; 1995 Jun; 21(6):1719-24. PubMed ID: 7768517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination].
    Tomás A; Soriano G; Guarner C; Teixidó M; Méndez C; Tena F; Fábrega E; Villanueva C; Such J; Balanzó J
    Rev Esp Enferm Dig; 1991 Apr; 79(4):259-64. PubMed ID: 2054213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination].
    Aparicio JR; Such J; Gutiérrez A; Pérez-Mateo M; Plaza J; Arroyo A
    Med Clin (Barc); 1999 Sep; 113(7):241-5. PubMed ID: 10544377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
    Fernández J; Ruiz del Arbol L; Gómez C; Durandez R; Serradilla R; Guarner C; Planas R; Arroyo V; Navasa M
    Gastroenterology; 2006 Oct; 131(4):1049-56; quiz 1285. PubMed ID: 17030175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of oral ciprofloxacin as selective intestinal decontaminant in cirrhosis.
    Borzio M; Salerno F; Saudelli M; Galvagno D; Piantoni L; Fragiacomo L
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):262-6. PubMed ID: 9646219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.
    Novella M; Solà R; Soriano G; Andreu M; Gana J; Ortiz J; Coll S; Sàbat M; Vila MC; Guarner C; Vilardell F
    Hepatology; 1997 Mar; 25(3):532-6. PubMed ID: 9049193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages.
    Terg R; Llano K; Cobas SM; Brotto C; Barrios A; Levi D; Wasen W; Bartellini MA
    J Hepatol; 1998 Sep; 29(3):437-42. PubMed ID: 9764991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient.
    Karp JE; Dick JD; Merz WG
    Eur J Cancer Clin Oncol; 1988; 24 Suppl 1():S5-13. PubMed ID: 3127219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock.
    Llovet JM; Bartolí R; Planas R; Viñado B; Pérez J; Cabré E; Arnal J; Ojanguren I; Ausina V; Gassull MA
    Hepatology; 1996 Apr; 23(4):781-7. PubMed ID: 8666332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.
    Ginés P; Rimola A; Planas R; Vargas V; Marco F; Almela M; Forné M; Miranda ML; Llach J; Salmerón JM
    Hepatology; 1990 Oct; 12(4 Pt 1):716-24. PubMed ID: 2210673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract.
    Karp JE; Merz WG; Hendricksen C; Laughon B; Redden T; Bamberger BJ; Bartlett JG; Saral R; Burke PJ
    Scand J Infect Dis Suppl; 1986; 48():66-78. PubMed ID: 3535055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Norfloxacin for selective decontamination: a study in human volunteers.
    De Vries-Hospers HG; Welling GW; Van der Waaij D
    Prog Clin Biol Res; 1985; 181():259-62. PubMed ID: 3161087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.
    Grangé JD; Roulot D; Pelletier G; Pariente EA; Denis J; Ink O; Blanc P; Richardet JP; Vinel JP; Delisle F; Fischer D; Flahault A; Amiot X
    J Hepatol; 1998 Sep; 29(3):430-6. PubMed ID: 9764990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of aztreonam on the fecal aerobic flora in children].
    Borderon JC; Rastegar A; Ramponi N; Gold F; Laugier J
    Pathol Biol (Paris); 1987 May; 35(5):665-8. PubMed ID: 3112714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage.
    Soriano G; Guarner C; Tomás A; Villanueva C; Torras X; González D; Sainz S; Anguera A; Cussó X; Balanzó J
    Gastroenterology; 1992 Oct; 103(4):1267-72. PubMed ID: 1397884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manipulation of the oropharyngeal and intestinal microflora by norfloxacin: microbiological and clinical aspects.
    Edlund C; Nord CE
    Scand J Infect Dis Suppl; 1988; 56():14-21. PubMed ID: 3074461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic administration of oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemias.
    Liso V; Specchia G; Pavone V; Pansini N; Capalbo S; Ostuni A; Mastria A; Colucci A; Costantino G
    J Chemother; 1989 Jul; 1(4 Suppl):1297-9. PubMed ID: 16312873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.